Transcatheter mitral valve interventions

Prog Cardiovasc Dis. 2021 Nov-Dec:69:84-88. doi: 10.1016/j.pcad.2021.11.005. Epub 2021 Nov 22.

Abstract

While there are dozens of novel transcatheter mitral devices in various stages of development, they remain years away from FDA approval. The existing approved transcatheter mitral interventions-transcatheter edge to edge repair for primary and secondary mitral regurgitations and transcatheter mitral valve-in-valve and valve-in-ring procedures for failing surgical prostheses-have seen a marked increase in both use and published data over the past several years. Transcatheter edge to edge repair with MitraClip has revolutionized the management of functional mitral regurgitation in heart failure with demonstrated reductions in mortality and heart failure hospitalization and is an appropriate option for patients with primary mitral regurgitation at high or prohibitive surgical risk. In patients with failing surgical mitral prostheses transcatheter mitral valve-in-valve and valve-in-ring procedures are an appealing alternative to repeat mitral valve surgery. Existing data and relevant concerns for these procedures are discussed herein.

Keywords: Mitral valve disease; Transcatheter edge to edge Repair; Transcatheter mitral valve replacement; Transcatheter therapeutics.

Publication types

  • Review

MeSH terms

  • Cardiac Catheterization*
  • Heart Failure / surgery
  • Humans
  • Mitral Valve / surgery
  • Mitral Valve Insufficiency* / surgery
  • Treatment Outcome